

Fax: 866-926-0463 Phone: 855-427-4682

Neuromuscular Disorder Enrollment Form for Achalasia, Chronic Anal Fissure, Detrusor Overactivity, Spasticity, Blepharospasm

Please complete this form for OptumRx members needing a Botulinum prescription. This form helps OptumRx determine if the patient's condition meets drug policy guidelines for coverage of the medications listed below in the Prescription Information section. Please fill out the form completely. Any missing information may cause a delay in the coverage determination. This form is not a valid prescription in Arizona or Virginia.

PATIENT INFORMATION					PRESCRIBER INFORMATION					
Please complete the following or send patient demographic sheet					Prescriber's Name					
Patient Name					DEA					
Address					NPI					
Address 2					Group/Hospital					
City, State, ZIP					Address					
Home Phone Alternate Phone					City, State, ZIP					
DOB Last Four of SS# Gender					Phone Fax					
Language Preference: English Spanish Other					Contact Perso	Contact Person Phone				
INSURANCE INFORMATION (Fill out entirely or fax a copy of patient's insurance card including both sides)										
Prescription Card: Name of Insurer ID # .						•				
Primary Insuran					Name of Insurer Phone Name of Insurer Phone					
Secondary Insurance: Subscriber ID # _					Name of	Insurer	Phone			
CLINICAL INFORMATION (Section must be completed to process prescription) (Attach separate sheet if needed)										
Diagnosis — Please include diagnosis name with ICD-10 code										
ICD-10 Code: _	CD-10 Code:				Diagnosis:					
Therapy:	New Reauthorization	Restart	Weigh	ıt	kg/lbs	Height	cm/in			
Allergies					Accompanying	g Medications	edications			
Yes No Does the provider attest to the member's medical record documenting both of the following?: 1. History and physical examination documenting the severity of the condition; and 2. Laboratory results or diagnostic evidence supporting the indication for which botulinum toxin is requested?										
If restart or reauthorization										
	No Did the member have	ve a positive cl	linical response	to botulinum t	toxin therapy?					
Achalasia: Yes No Diagnosis of achalasia has been confirmed by esophageal manometry?										
Yes No Has patient failed or is not a candidate for pneumatic dilation or myotomy?										
Yes No Does member has history of failure, contraindication, or intolerance to one of the following: A. Calcium channel blocker or B. Long-acting nitrate?										
Yes No Have other causes of dysphagia (e.g., peptic stricture, carcinoma, extrinsic compression) ruled out by upper gastrointestinal endoscopy? Chronic anal fissure:										
Yes No Have the symptoms been ongoing for at least two months?										
Yes Does member have one of the following: Nocturnal pain and bleeding OR Postdefecation pain? Yes No Does member have history of failure, contraindication, or intolerance to one of the following conventional therapies:										
Yes Does member have history of failure, contraindication, or intolerance to one of the following conventional therapies: A. Topical nitrate or B. Topical calcium channel blocker (diltiazem or nifedipine)										
Detrusor Overactivity										
Yes Does member have history of failure, contraindication, or intolerance to two anticholinergic medications? (Such as: darifenacin, fesoterodine, oxybutynin, solifenacin, tolterodine, trospium)										
Spasticity No. Spasticity associated with any of the following: carebral palsy: multiple sclerosis: payromyelitic optica (NMO): stroke or other injury disease or tumor										
Yes No Spasticity associated with any of the following: cerebral palsy; multiple sclerosis; neuromyelitis optica (NMO); stroke or other injury, disease, or tumor of the brain or spinal cord?										
	m associated with Dystonia No Does the member h		•		intolerance to Bo	tox (onabotulinumtoxinA)?				
Yes No Does the member have a history of failure, contraindication, or intolerance to Botox (onabotulinumtoxinA)? PRESCRIPTION INFORMATION										
Medication	Dose/Strei					Directions		Quantity	Refills	
Botox®	50 Unit Vial 100 U	Unit Vial	200 Unit Vial	Inject	_units IM intoe	every(weeks/months).	To be given by MD in office, any unused portion to be discarded.			
Dysport®	300 Unit Vial 500	Unit Vial		Inject	_units IM into	every (weeks/months).	To be given by MD in office, any unused portion to be discarded.			
	2,500 Unit Vial 5,0	000 Unit Vial								
☐ Myobloc®	10,000 Unit Vial			nject	_units IM into	every(weeks/months).	To be given by MD in office, any unused portion to be discarded.			
Xeomin®		0 Unit Vial		☐ Inject	_units IM intoe	every(weeks/months).	To be given by MD in office, any unused portion to be discarded.			
					•					
Ship to: Office Office Date Needed *Prescriber Authorization: I authorize this pharmacy and its representatives to act as my authorized agent to secure coverage and initiate the insurance prior authorization process for my patient(s), and to sign any necessary forms on my behalf as my										
**Prescriber Authorization: Lauthorize this pharmacy and its representatives to act as my authorized agent to secure coverage and initiate the insurance prior authorization process for my patientist, and to sign any necessary forms on my behalf as authorized agent, including the receipt of any required prior authorization forms and the receipt and submission of patient lab values and other patient data. In the event that this pharmacy determines that it is unable to fulfill this prescription, I further authorize this pharmacy to forward this information and any related materials related to coverage of the product to another pharmacy of the patient's choice or in the patient's insurer's provider network.										
Product Substitution permitted Dispense as Written										
Prescriber's Supervising										
Signature Date physician Date Date										
CONFIDENTIALITY STATEMENT: This communication is intended for the use of the individual or entity to which it is addressed and may contain information that is privileged, confidential, and exempt from disclosure under applicable law If the reader of										

CONFIDENTIALITY STATEMENT: This communication is intended for the use of the individual or entity to which it is addressed and may contain information that is privileged, confidential, and exempt from disclosure under applicable law if the reader of this communication is not the intended recipient or the employee or agent responsible for delivery of the communication, you are hereby notified that any dissemination, distribution, or copyling of the communication is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone. This form is not a valid prescription in Arizona or Virginia.